PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 6, 2023EP Europace78 citationsOpen Access

STereotactic Arrhythmia Radioablation (STAR): the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe

View Full Paper
MGMelanie GrehnUniversity Hospital Schleswig-HolsteinSMStefano MandijaUtrecht UniversityMMMarcin MiszczykComprehensive Cancer Center Vienna

Key Result

A survey of 31 European institutions revealed that while the majority apply a single-fraction dose of 25 Gy for STereotactic Arrhythmia Radioablation, planning and dose prescription methods vary greatly.

Study Design

Type

Cross-Sectional (n=31)

Multicenter

Yes

Structured PICO

P
Population
31 clinical and research institutions in Europe surveyed on their current clinical practice of STereotactic Arrhythmia Radioablation for ventricular tachycardia.
E
Exposure
STereotactic Arrhythmia Radioablation (STAR)
O
Outcome
Current clinical STAR practice patterns in Europe (target definition, dosing, planning techniques)

The STOPSTORM consortium highlights significant variation in current clinical STAR practice across Europe, identifying areas for optimization and harmonization in substrate mapping, target delineation, and dosimetry.

Abstract

The EU Horizon 2020 Framework-funded Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary (STOPSTORM) consortium has been established as a large research network for investigating STereotactic Arrhythmia Radioablation (STAR) for ventricular tachycardia (VT). The aim is to provide a pooled treatment database to evaluate patterns of practice and outcomes of STAR and finally to harmonize STAR within Europe. The consortium comprises 31 clinical and research institutions. The project is divided into nine work packages (WPs): (i) observational cohort; (ii) standardization and harmonization of target delineation; (iii) harmonized prospective cohort; (iv) quality assurance (QA); (v) analysis and evaluation; (vi, ix) ethics and regulations; and (vii, viii) project coordination and dissemination. To provide a review of current clinical STAR practice in Europe, a comprehensive questionnaire was performed at project start. The STOPSTORM Institutions' experience in VT catheter ablation (83% ≥ 20 ann.) and stereotactic body radiotherapy (59% > 200 ann.) was adequate, and 84 STAR treatments were performed until project launch, while 8/22 centres already recruited VT patients in national clinical trials. The majority currently base their target definition on mapping during VT (96%) and/or pace mapping (75%), reduced voltage areas (63%), or late ventricular potentials (75%) during sinus rhythm. The majority currently apply a single-fraction dose of 25 Gy while planning techniques and dose prescription methods vary greatly. The current clinical STAR practice in the STOPSTORM consortium highlights potential areas of optimization and harmonization for substrate mapping, target delineation, motion management, dosimetry, and QA, which will be addressed in the various WPs.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Grehn et al. (2023) conducted a cross-sectional in Ventricular tachycardia (n=31). STereotactic Arrhythmia Radioablation (STAR) was evaluated on Current clinical STAR practice patterns. A survey of 31 European institutions revealed that while the majority apply a single-fraction dose of 25 Gy for STereotactic Arrhythmia Radioablation, planning and dose prescription methods vary greatly.

synapsesocial.com/papers/6a2229fee8ef4064f24ec86bhttps://doi.org/10.1093/europace/euac238
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Stereotactic management of arrhythmia – radiosurgery in treatment of ventricular tachycardia (SMART-VT) – clinical trial protocol and study rationale2021 · 7 citations
  2. 2Stereotactic Radiotherapy for the Management of Refractory Ventricular Tachycardia: Promise and Future Directions2020 · 37 citations
  3. 3Accuracy of electroanatomical mapping-guided cardiac radiotherapy for ventricular tachycardia: pitfalls and solutions2021 · 32 citations
  4. 4Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: An International VT Ablation Center Collaborative Group study2015 · 502 citations
  5. 5Under-reported dosimetry errors due to interplay effects during VMAT dose delivery in extreme hypofractionated stereotactic radiotherapy2018 · 27 citations